Fig. 2
KM and parametric survival distributions for iDFS iDFS, invasive disease-free survival; ABE + ET: abemaciclib + endocrine therapy; ET: endocrine therapy
Fig. 2 | Cost Effectiveness and Resource Allocation
KM and parametric survival distributions for iDFS iDFS, invasive disease-free survival; ABE + ET: abemaciclib + endocrine therapy; ET: endocrine therapy